109103 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression; Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR (FGF21) CODING SEQUENCE
#2GENETICALLY MODIFIED MOUSE FOR PREPARING ANTIBODY AND METHOD FOR PREPARING GENETICALLY MODIFIED MOUSE
#3Circular RNA For Translation In Eukaryotic Cells
#4Circular RNA For Translation In Eukaryotic Cells
#5GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY-CHAIN ANTIBODIES
#6MICE THAT MAKE VL BINDING PROTEINS
#7NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS
#8BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS
#9HUMAN IMMUNOGLOBULIN COMMON LIGHT CHAIN TRANSGENE CONSTRUCTS AND USES THEREOF
#10OX40-Binding Polypeptides and Uses Thereof
#11NON-HUMAN ANIMALS EXPRESSING EXOGENOUS TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE
#12MOUSE ARTIFICIAL CHROMOSOME VECTOR AND USE THEREOF
#13ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#14ANTI-KRAS-G12D T CELL RECEPTORS
#15METHOD FOR PRODUCING RECOMBINANT PROTEINS IN INSECTS FOR INTEGRATION IN HUMAN THERAPEUTICS
#16Silk Gland Recombinant Expression Vector of Silkworm (Bombyx Mori) Expressing Human Epidermal Growth Factor, Preparation Method and Use Thereof
#17METHODS FOR PRODUCING ANTIGEN-BINDING PROTEINS AGAINST FOREIGN ANTIGENS
#18HUMAN ALPHA-GALACTOSIDASE VARIANTS
#19OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#20HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
#21NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
#22METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS
#23COMPOSITION FOR TREATMENT OF SEPSIS BY REGULATING OLFR164
#24A NON-HUMAN MAMMAL COMPRISING IN ITS GENOME AT LEAST TWO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I ALLELES, METHODS OF MAKING SUCH MAMMAL AND USES THEREOF
#25Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell Types
#26TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#27TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#28COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF OBTAINING THE COMPOSITIONS THEREOF
#29OX40-Binding Polypeptides and Uses Thereof
#30MAMMALIAN ARTIFICIAL CHROMOSOME VECTOR HAVING HUMAN IMMUNOGLOBULIN HEAVY CHAIN LOCUS COMPRISING MODIFIED D-REGION, AND CELL OR NON-HUMAN ANIMAL RETAINING THE VECTOR
#31ANTI-CD25 ANTIBODY AGENTS
#32Optimized RPE65 Promoter and Coding Sequences
#33Circular RNA For Translation In Eukaryotic Cells
#34METHOD FOR PRODUCING AN IMMUNOCONJUGATE
#35mRNA display antibody library and methods
#36ENGINEERED NON-HUMAN ANIMALS FOR PRODUCING ANTIBODIES
#37VARIANT OF A BPIFB4 PROTEIN
#38RECOMBINANT GENOME, AND NON-HUMAN MAMMALIAN CELL AND PRODUCTION METHOD THEREFOR AND USE THEREOF
#39COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION
#40ANTI-KRAS-G12D T CELL RECEPTORS
#41Methods of Treating Muscular Dystrophy
#42ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
#43ANTI-PD-1 ANTIBODIES AND USES THEREOF
#44VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE
#45LONG GERMLINE DH GENES AND LONG HCDR3 ANTIBODIES
#46Circular RNA For Translation In Eukaryotic Cells
#47RECOMBINANT GENOME, AND NON-HUMAN MAMMALIAN CELL AND PRODUCTION METHOD THEREFOR AND USE THEREOF
#48BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
#49THERAPEUTIC ANTIBODIES
#50TRANSPOSON-BASED VECTORS AND USES
#51OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#52ANTI-TAU ANTIBODIES AND USES THEREOF
#53CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA
#54TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN
#55CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF
#56AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN
#57TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
#58ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY
#59Promoter of Hspa5 Gene
#60GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD38
#61FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
#62TRANSGENIC MICE
#63OX40-binding polypeptides and uses thereof
#64METHOD FOR PRODUCING RECOMBINANT PROTEINS IN INSECTS
#65Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
#66IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT
#67BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITONS AND METHODS THEREOF, FOR TREATMENT OF CANCER AND OTHER DISEASES
#68Compositions and Methods for Enhancing Beta Cell Maturation, Health and Function
#69AAV VARIANTS WITH HOST ANTIBODY ESCAPE CAPABILITIES AND ALTERED TISSUE TARGETING PROPERTIES
#70Human interleukin-4 receptor alpha antibodies
#71HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
#72NOVEL ANTI-FGFR2B ANTIBODIES
#73Circular RNA for translation in eukaryotic cells
#74DIRECT SELECTION OF CELLS EXPRESSING HIGH LEVELS OF HETEROMERIC PROTEINS USING GLUTAMINE SYNTHETASE INTRAGENIC COMPLEMENTATION VECTORS
#75METHODS AND SYSTEMS FOR TREATING OR PREVENTING PREGNANCY-RELATED HYPERTENSIVE DISORDERS
#76METHODS OF DETECTING ALLOANTIBODIES TO HLA CLASS II ANTIGENS
#77PRODUCTION OF RECOMBINANT PROTEINS USING FAH AS THE SELECTION MARKER
#78ANTI-ROR1 ANTIBODIES AND COMPOSITIONS
#79Therapeutic antibodies
#80Human alpha-galactosidase variants
#81PLATFORM FOR THE INDUCTION & MAINTENANCE OF GROUND STATE PLURIPOTENCY
#82Methods and compositions related to recombinant NEIL2
#83Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof
#84EXPRESSION OF PRODUCTS FROM NUCLEIC ACID CONCATEMERS
#85Ciliary Neurotrophic Factor Receptor Ligands and Methods of Using the Same
#86ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
#87ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#88MICE THAT MAKE VL BINDING PROTEINS
#89Variant of a BPIFB4 protein
#90METHODS FOR PRODUCING ANTIGEN-BINDING PROTEINS AGAINST FOREIGN ANTIGENS
#91ANTI-C5A ANTIBODIES AND USES THEREOF
#92NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#93NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#94MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
#95TRANSGENIC MOUSE EXPRESSING COMMON HUMAN LIGHT CHAIN
#96Anti-KRAS-G12D T cell receptors
#97Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
#98APPLICATION OF UTX GENE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING LIPID DISEASES
#99METHODS AND COMPOSITIONS FOR PREPARING SURFACTANT PROTEIN D (SP-D)
#100Circular RNA for translation in eukaryotic cells
#101Synthesis of Non-Native Proteins in Bombyx Mori by Modifying Sericin Expression
#102Synthesis of High Molecular Weight Proteins Using Inteins
#103AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
#104Recombinant porcine parvovirus antigenic protein and use thereof
#105Circular RNA for translation in eukaryotic cells
#106Insect toxin delivery mediated by a densovirus coat protein
#107METHODS, COMPOSITIONS AND SYSTEMS FOR PRODUCTION OF RECOMBINANT SPIDER SILK POLYPEPTIDES
#108Compositions and methods for differentiation of human pluripotent stem cells into desired cell types
#109NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
#110TCR libraries
#111Circular RNA for translation in eukaryotic cells
#112SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
#113Method for preparing fish skin mucous gland bioreactor and application thereof
#114Anti-KRAS-G12D T cell receptors
#115GENETICALLY-MODIFIED POULTRY EGG
#116mRNA display antibody library and methods
#117COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES
#118NON-HUMAN ANIMALS CAPABLE OF DH-DH REARRANGEMENT IN THE IMMUNOGLOBULIN HEAVY CHAIN CODING SEQUENCES
#119Non-human animals having a humanized signal-regulatory protein gene
#120Antibodies useful for detection of human carcinoma antigen
#121GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS TARGETING GANGLIOSIDE BIOSYNTHETIC PATHWAYS
#122Circular RNA for translation in eukaryotic cells
#123Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
#124Expression from transposon-based vectors and uses
#125Anti-rho GTPase conformational single domain antibodies and uses thereof
#126MICE THAT MAKE VL BINDING PROTEINS
#127MOUSE ARTIFICIAL CHROMOSOME VECTOR AND USE THEREOF
#128Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
#129Antibody for binding to interleukin 4 receptor
#130ADAM6 KNOCKIN MICE
#131Anti-CD25 antibody agents
#132GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF
#133Anti-CD25 for tumour specific cell depletion
#134Anti-CD25 for tumour specific cell depletion
#135Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof
#136INDUCIBLE DISEASE MODELS METHODS OF MAKING THEM AND USE IN TISSUE COMPLEMENTATION
#137NON-HUMAN GENE-EDITED MAMMAL, PROTEIN CRUDE EXTRACT SEPARATED FROM CONNECTIVE TISSUE OF NON-HUMAN GENE-EDITED MAMMAL, METHOD FOR PROTEIN CRUDE EXTRACT AND USES OF PROTEIN CRUDE EXTRACT
#138NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS
#139Anti-Tau antibodies and uses thereof
#140NUCLEIC ACID MOLECULES AND APPLICATIONS THEREOF IN PREPARING HUMAN SINGLE-DOMAIN ANTIBODY
#141Viral vector suitable for gene therapy encoding a variant of a BPIFB4 protein
#142Anti-CD25 for tumour specific cell depletion
#143Anti-CD25 for tumour specific cell depletion
#144Anti-CD25 for tumour specific cell depletion
#145Anti-CD25 antibody agents
#146Nucleic acid molecules and applications thereof in human antibody
#147MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production
#148METHODS, COMPOSITIONS AND CELLS FOR PREPARING SURFACTANT PROTEIN D (SP-D)
#149Anti-CD25 antibody agents
#150EXPRESSION OF PRODUCTS FROM NUCLEIC ACID CONCATEMERS
#151A METHOD FOR GENOME EDITING IN A HOST CELL
#152NOVEL CRISPR ENZYMES AND SYSTEMS
#153Cellobiohydrolase variants and polynucleotides encoding same
#154Chimeric antigen receptors targeted to PSCA
#155Fast-off rate serum albumin binding fibronectin type III domains
#156GENERATION OF HEAVY-CHAIN ONLY ANTIBODIES IN TRANSGENIC ANIMALS
#157Antibody for binding to interleukin 4 receptor
#158Anti-KRAS-T cell receptors
#159Gene-modified mouse expressing human GPC3 polypeptide
#160Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
#161Transgenic Animals
#162Human alpha-galactosidase variants
#163Non-human animals having a humanized signal-regulatory protein gene
#164Optimized RPE65 promoter and coding sequences
#165Anti-ALK antibodies and methods for use thereof
#166Anti-CD3 antibodies and methods of making and using thereof
#167Anti-ROBO2 antibodies, compositions, methods and uses thereof
#168Anti-PD-L1 nanobody, coding sequence and use thereof
#169Anti-C5a antibodies and uses thereof
#170COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
#171T cell receptors and immune therapy using the same
#172Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
#173Bispecific antibodies against CEACAM5 and CD47
#174Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
#175Anti-PD-1 antibodies and uses thereof
#176AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN
#177INNOVATIVE PREPARATION PROCESS FOR BMP-2 STEM CELLS
#178VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE
#179METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2
#180COMPOSITIONS AND METHODS FOR PRODUCING EXOSOME LOADED THERAPEUTICS FOR TREATING CARDIOVASCULAR DISEASE
#181Recombinant adenovirus-based interferon biotherapeutics in swine
#182Circular RNA for translation in eukaryotic cells
#183SELF-LIMITING CAS9 CIRCUITRY FOR ENHANCED SAFETY (SLICES) PLASMID AND LENTIVIRAL SYSTEM THEREOF
#184METHODS OF DETECTING ALLOANTIBODIES TO HLA CLASS II ANTIGENS
#185ANIMAL MODELS AND THERAPEUTIC MOLECULES
#186OX40-binding polypeptides and uses thereof
#187APPLICATION OF UTX GENE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING LIPID DISEASES
#188MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
#189METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS
#190NON-HUMAN ANIMALS CAPABLE OF ENGINEERED DH-DH REARRANGEMENT AND USES THEREOF
#191VHH antibody
#192VIRAL METHODS OF T CELL THERAPY
#193Therapeutic antibodies
#194Recombinant protein production system
#195METHOD FOR PRODUCING AN IMMUNOCONJUGATE
#196Anti-CD3 antibody and molecules comprising the antibody
#197AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
#198FACTOR X VARIANTS
#199Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
#200Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer
#201GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE
#202A CELL-BASED ARRAY PLATFORM
#203Ciliary neurotrophic factor receptor ligands and methods of using the same
#204A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION
#205Anti-CD25 antibody agents
#206Engineered B cells and related compositions and methods
#207Transgenic animal for production of antibodies having minimal CDRs
#208Recombinant RSV antigens, nucleic acid molecules encoding the antigens, and vaccine compositions comprising the same
#209IL-13 antibody and preparation method and use thereof
#210HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
#211Anti-CD25 antibody agents
#212GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF
#213PDL1 block CAR-T transgenic vector for suppressing immune escape, preparation method thereof, and application of the same
#214Anti-CD25 antibody agents
#215BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3
#216IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT
#217Production cell line enhancers
#218mRNA display antibody library and methods
#219Antibodies useful for detection of human carcinoma antigen
#220BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS
#221T cell receptors and immune therapy using the same
#222Human antibody-producing non-human animal and method for preparing human antibodies using same
#223Antibody to programmed cell death 1 (PD-1) and use thereof
#224Promoter of Hspa5 gene
#225Insect toxin delivery mediated by a densovirus coat protein
#226SYSTEM AND METHOD FOR CHARACTERIZING DRUG PRODUCT IMPURITIES
#227METHODS AND COMPOSITIONS FOR T-CELL EPITOPE SCREENING
#228Platform for the induction and maintenance of ground state pluripotency
#229Method of preparing T cells with increased activity
#230Synthetic antibodies against VEGF and their uses
#231HOST CELLS WITH ENHANCED PROTEIN EXPRESSION EFFICIENCY AND USES THEREOF
#232Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein
#233Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
#234Expression from transposon-based vectors and uses
#235Monoclonal antibody against MELK and utilization thereof
#236Anti-PD-L1 nanobody, coding sequence and use thereof
#237Anti-CTLA4 antibodies
#238ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
#239Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
#240Anti-KRAS-G12D T cell receptors
#241GENE-MODIFIED NON-HUMAN ANIMAL EXPRESSING HUMAN GPC3 POLYPEPTIDE
#242Anti-LAG-3 antibody
#243Modified anti-tenascin antibodies and methods of use
#244COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES
#245COMPOSITIONS AND METHODS RELATED TO THERAPEUTIC CELL SYSTEMS EXPRESSING EXOGENOUS RNA
#246Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
#247Anti-human interleukin-17A monoclonal antibody
#248ANTI-GALACTAN II MONOCLONAL ANTIBODIES TARGETING KLEBSIELLA PNEUMONIAE
#249Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
#250Anti-PD-1 antibodies and uses thereof
#251Transgenic animal for production of antibodies having minimal CDRs
#252Long germline DH genes and long HCDR3 antibodies
#253Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
#254Non-human animals having a humanized signal-regulatory protein gene
#255Humanized anti-rage antibody
#256Methods, compositions and systems for production of recombinant spider silk polypeptides
#257Anti-Tau antibodies and uses thereof
#258Anti-tau antibodies and uses thereof
#259Engineered polypeptides for antigen delivery
#260Transgenic rabbit with common light chain
#261Transgenic cloned piglet expressing human proinsulin and method of producing the same
#262Cellobiohydrolase variants and polynucleotides encoding same
#263TRANSGENE EXPRESSION IN AVIANS
#264CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION
#265Methods and compositions for preparing surfactant protein D (SP-D)
#266Methods, compositions and cells for preparing surfactant protein D (SP-D)
#267TCR libraries
#268Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
#269INDUCIBLE DISEASE MODELS METHODS OF MAKING THEM AND USE IN TISSUE COMPLEMENTATION
#270Method for producing antibody
#271Genetically modified chicken egg with an exogenous sequence knocked into the ovalbumin gene
#272T cell receptors and immune therapy using the same
#273Targeted disruption of T cell and/or HLA receptors
#274Transgenic mice
#275Methods of treating muscular dystrophy
#276Transgenic animal for production of antibodies having minimal CDRS
#277METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS
#278Anti-canine TARC antibody used for treatment and diagnosis of canine atopic dermatitis
#279MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production
#280Animal models and therapeutic molecules
#281High-throughput mouse model for optimizing antibody affinities
#282Transgenic Animals
#283Chimaeric Surrogate Light Chains (SLC) Comprising Human VpreB
#284Genetically engineered larvae for wound healing
#285EFFICIENT AND SAFE TRANSPOSON INTEGRATION SYSTEM AND USE THEREOF
#286Fast-off rate serum albumin binding fibronectin type III domains
#287Compositions and methods for differentiation of human pluripotent stem cells into desired cell types
#288Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
#289Human IL-15-secreting immunodeficient mouse
#290Non-human animal having human CD3 gene substituted for endogenous CD3 gene
#291Non-HLA matched humanized NSG mouse model with patient-derived xenograft
#292Compositions and methods for enhancing gene expression
#293NATIVE PROTEIN PURIFICATION TECHNOLOGY
#294Non-human animals having a humanized signal-regulatory protein gene
#295Non-human animals having an engineered immunoglobulin Λ light chain locus
#296Optimized RPE65 promoter and coding sequences
#297METHODS OF USING FIBROBLAST GROWTH FACTOR (FGF) 1 WITH MUTATION IN THE HEPARIN BINDING DOMAIN AND METHODS TO REDUCE BLOOD GLUCOSE
#298Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
#299Sequence variants
#300HCO32 and HCO27 and related examples